#None #immunofluorescence #Revolune #Propath UK

Enhancing Biopharma Research: Revolune and Propath UK Partnership

In a significant move for the biopharmaceutical sector, Revolune has announced a collaborative partnership with Propath UK, aimed at facilitating easier access to its advanced multiplex immunofluorescence workflow. This partnership is poised to make a profound impact on research methodologies, ensuring researchers and translational teams can adopt innovative multiplex immunofluorescence workflows with greater flexibility.

The collaboration allows Propath UK to become a part of Revolune’s Service Provider Program, enabling customers to effectively utilize Revolune's technologies in multiple ways. This includes the option to conduct their assays internally or leverage Propath UK’s expertise through its dedicated service laboratory in the UK. The service is particularly designed for those researchers who seek support in optimizing antibody usage, developing multiplex panels, or managing complex data from tissue processing to imaging.

A Flexible Approach to Research

Adrian Arechiga, Revolune's Chief Commercial Officer, emphasized the importance of a flexible system when adopting multiplex immunofluorescence. He explained, “Our technology allows labs to move seamlessly from utilizing primary antibodies to deploying ready-to-use multiplex workflows. By partnering with Propath UK, we extend a crucial layer of service support that enables clients to access cutting-edge technology while receiving guidance from specialized professionals.”

With Propath UK's diverse expertise encompassing pathology, immunohistochemistry, and spatial transcriptomics, this partnership is expected to enhance the capability of researchers to produce actionable insights quickly and efficiently. This alignment comes at a crucial moment when many in the research community are exploring flexible options as they transition from traditional workflows that have stifled innovation.

Comprehensive Support from Start to Finish

The collaboration between Revolune and Propath UK is designed to encompass all aspects of the multiplex workflow process. Not only do they provide assistance in antibody optimization and multiplex panel development, but they also facilitate performance across imaging, bioinformatics, and GCP-compliant tissue biomarker analysis for clinical trials. Propath's experts will accompany clients from the initial study design through sample qualification, delivering crucial insights based on complex tissue analyses.

Kelly Hunter, Chief Scientific Officer at Propath, noted the significance of their experience in supporting clients with complex biomarker workflows. She stated, “Accessing Revolune’s technology through a service model is valuable, particularly for teams hesitant to build every capability in-house from the outset.” This supportive framework is especially beneficial for organizations in the biopharma sector looking to bridge technology gaps without excessive resource expenditure.

Aiming for the Future of Biopharma Research

Propath UK has gained a reputation for providing assistance in deploying complex workflows across various studies and has successfully supported numerous projects in the global biopharmaceutical landscape. This partnership is part of Revolune’s broader objective to create a robust Service Provider model that would be scalable across geographies, product applications, and client service needs.

About Revolune: Revolune stands at the forefront of life sciences, dedicated to making multiplex immunofluorescence accessible akin to routine tissue analysis. Their innovative reagent technologies enable labs to transition quickly from traditional antibody use to ready-to-go multiplex kits, thereby simplifying spatial biology workflows and allowing researchers to concentrate on pivotal biological queries.

About Propath UK: Identifying itself as The Spatial Biology CRO®, Propath UK has positioned itself to fulfill the need for high-quality, GCP-compliant spatial transcriptomic and proteomic research services tailored to the global biopharma industry. With over 35 years of experience, Propath continues to deliver exceptional research support that advances the field of biopharma and therapeutic developments.

In conclusion, this partnership between Revolune and Propath UK not only represents a strategic alliance but also a promising step towards evolving the landscape of biomarker research and implementation within biopharma, enabling faster and more flexible approaches to complex tissue-based studies. This dynamic initiative is set to revolutionize how researchers can conduct their investigations and ultimately lead to breakthroughs in therapeutic developments.